State Board of Administration of Florida Retirement System boosted its position in Repligen Corp. (NASDAQ:RGEN) by 2.9% during the second quarter, Holdings Channel reports. The institutional investor owned 20,948 shares of the company’s stock after buying an additional 588 shares during the period. State Board of Administration of Florida Retirement System owned about 0.06% of Repligen Corp. worth $573,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. Acrospire Investment Management LLC purchased a new stake in shares of Repligen Corp. during the first quarter worth about $106,000. Legal & General Group Plc increased its stake in shares of Repligen Corp. by 10.2% in the first quarter. Legal & General Group Plc now owns 6,737 shares of the company’s stock worth $184,000 after buying an additional 623 shares in the last quarter. BB&T Corp purchased a new stake in shares of Repligen Corp. during the second quarter worth about $241,000. BNP Paribas Arbitrage SA increased its stake in shares of Repligen Corp. by 122.3% in the second quarter. BNP Paribas Arbitrage SA now owns 10,542 shares of the company’s stock worth $288,000 after buying an additional 5,800 shares in the last quarter. Finally, Boston Advisors LLC increased its stake in shares of Repligen Corp. by 34.7% in the second quarter. Boston Advisors LLC now owns 13,755 shares of the company’s stock worth $376,000 after buying an additional 3,540 shares in the last quarter. Institutional investors and hedge funds own 89.38% of the company’s stock.
Repligen Corp. (NASDAQ:RGEN) traded up 0.53% during mid-day trading on Wednesday, reaching $30.30. 74,131 shares of the company traded hands. The stock has a market capitalization of $1.02 billion, a PE ratio of 121.20 and a beta of 1.36. The stock has a 50-day moving average of $31.77 and a 200 day moving average of $27.77. Repligen Corp. has a 52-week low of $20.07 and a 52-week high of $36.00.
Repligen Corp. (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.03. Repligen Corp. had a net margin of 8.69% and a return on equity of 10.74%. The company had revenue of $29.20 million for the quarter, compared to the consensus estimate of $24.75 million. During the same quarter in the prior year, the firm earned $0.11 earnings per share. The company’s revenue for the quarter was up 35.8% compared to the same quarter last year. Equities research analysts expect that Repligen Corp. will post $0.44 earnings per share for the current year.
A number of analysts have recently issued reports on RGEN shares. Zacks Investment Research upgraded shares of Repligen Corp. from a “sell” rating to a “hold” rating in a report on Thursday, July 21st. Jefferies Group reiterated a “hold” rating and issued a $28.00 target price on shares of Repligen Corp. in a report on Monday, June 13th.
In related news, Director Thomas F. Ryan, Jr. sold 2,700 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $32.58, for a total transaction of $87,966.00. Following the transaction, the director now owns 9,394 shares of the company’s stock, valued at $306,056.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.30% of the company’s stock.
About Repligen Corp.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corp. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.